文献速递消化、代谢与肾脏急症

索托维单抗对高危轻中度COVID-19患者住院或死亡的影响:一项随机临床试验

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01
一句话结论非住院高危轻中度COVID-19患者单次静脉输注索托维单抗500 mg,第29天全因住院(>24小时)或死亡从6%降至1%(校正RR 0.21,95%CI 0.09-0.50;P<.001)。

这项在巴西、加拿大、秘鲁、西班牙和美国57个中心开展的随机临床试验,纳入1057例非住院、有症状的轻中度COVID-19且至少1项进展危险因素的患者,1:1随机接受单次静脉输注索托维单抗500 mg(n=528)或安慰剂(n=529)。主要终点第29天全因住院>24小时或死亡:索托维单抗组6/528(1%)vs 安慰剂组30/529(6%)(校正RR 0.21,95%CI 0.09-0.50;绝对差-4.53%,95%CI -6.70%至-2.37%;P<.001),因疗效在预设中期分析时提前终止入组。5项次要终点中4项达统计学显著,包括急诊就诊、任何时长住院或死亡复合终点(13/528[2%] vs 39/529[7%];校正RR 0.34,95%CI 0.19-0.63;P<.001)及进展为需吸氧或机械通气的重度/危重度呼吸性COVID-19(7/528[1%] vs 28/529[5%];校正RR 0.26,95%CI 0.12-0.59;P=.002)。不良事件少见且两组相似(22% vs 23%),最常见为索托维单抗组腹泻(n=8;2%)和安慰剂组COVID-19肺炎(n=22;4%)。作者认为该结果支持索托维单抗作为非住院高危轻中度COVID-19患者的治疗选择,但对研究完成后出现的SARS-CoV-2变异株的疗效未知。

要点

  • 研究人群为非住院、有症状的轻中度COVID-19且至少1项进展危险因素者;索托维单抗500 mg单次静脉输注,第29天住院>24小时或死亡1%(6/528)vs 安慰剂6%(30/529),校正RR 0.21(95%CI 0.09-0.50;P<.001)。
  • 急诊就诊、任何时长住院或死亡复合终点:索托维单抗2%(13/528)vs 安慰剂7%(39/529),校正RR 0.34(95%CI 0.19-0.63;P<.001)。
  • 进展为需吸氧或机械通气的重度/危重度呼吸性COVID-19:索托维单抗1%(7/528)vs 安慰剂5%(28/529),校正RR 0.26(95%CI 0.12-0.59;P=.002)。
  • 不良事件发生率索托维单抗22% vs 安慰剂23%;最常见不良事件分别为索托维单抗组腹泻(n=8;2%)和安慰剂组COVID-19肺炎(n=22;4%)。
  • 作者认为索托维单抗可作为非住院高危轻中度COVID-19患者的治疗选择,但对研究完成后出现的SARS-CoV-2变异株疗效未知。

适用人群与场景

  • 非住院、有症状的轻中度COVID-19患者,且至少1项疾病进展危险因素;中位年龄53岁(IQR 42-62),20%为≥65岁,65%为拉丁裔。
  • 研究在巴西、加拿大、秘鲁、西班牙和美国的57个中心开展,入组时间为2020年8月27日至2021年3月11日,随访数据收集至2021年4月8日。

处置流程与药物剂量

  • 索托维单抗500 mg单次静脉输注,用于非住院、有症状的轻中度COVID-19且至少1项进展危险因素的患者。
  • 对照为安慰剂静脉输注。

研究设计与关键结果

  • 随机临床试验,57个中心,纳入1057例非住院轻中度COVID-19伴至少1项进展危险因素的患者,1:1随机接受索托维单抗500 mg静脉输注(n=528)或安慰剂(n=529);因疗效在预设中期分析时提前终止入组。
  • 主要终点(第29天全因住院>24小时或死亡):索托维单抗6/528(1%)vs 安慰剂30/529(6%),校正RR 0.21(95%CI 0.09-0.50),绝对差-4.53%(95%CI -6.70%至-2.37%),P<.001。
  • 次要终点:急诊就诊、任何时长住院或死亡复合终点,索托维单抗13/528(2%)vs 安慰剂39/529(7%),校正RR 0.34(95%CI 0.19-0.63),绝对差-4.91%(95%CI -7.50%至-2.32%),P<.001。
  • 次要终点:进展为需吸氧或机械通气的重度/危重度呼吸性COVID-19,索托维单抗7/528(1%)vs 安慰剂28/529(5%),校正RR 0.26(95%CI 0.12-0.59),绝对差-3.97%(95%CI -6.11%至-1.82%),P=.002。
  • 5项次要终点中4项达统计学显著,均支持索托维单抗。
  • 不良事件少见且两组相似:索托维单抗22% vs 安慰剂23%;最常见不良事件为索托维单抗组腹泻(n=8;2%)和安慰剂组COVID-19肺炎(n=22;4%)。
  • 随访中位时间:索托维单抗组103天,安慰剂组102天。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 局限:因疗效在预设中期分析时提前终止入组;对研究完成后出现的SARS-CoV-2变异株的疗效未知。

对床旁实践的改变

  • 作者认为,对于非住院、有疾病进展风险的轻中度COVID-19患者,索托维单抗可作为治疗选择。
  • 作者指出,对研究完成后出现的SARS-CoV-2变异株的疗效未知。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Older patients and those with comorbidities who are infected with SARS-CoV-2 may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody for the treatment of high-risk patients to prevent COVID-19 progression.

OBJECTIVE: To evaluate the efficacy and adverse events of sotrovimab in preventing progression of mild to moderate COVID-19 to severe disease.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial including 1057 nonhospitalized patients with symptomatic, mild to moderate COVID-19 and at least 1 risk factor for progression conducted at 57 sites in Brazil, Canada, Peru, Spain, and the US from August 27, 2020, through March 11, 2021; follow-up data were collected through April 8, 2021.

INTERVENTIONS: Patients were randomized (1:1) to an intravenous infusion with 500 mg of sotrovimab (n = 528) or placebo (n = 529).

MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with COVID-19 progression through day 29 (all-cause hospitalization lasting >24 hours for acute illness management or death); 5 secondary outcomes were tested in hierarchal order, including a composite of all-cause emergency department (ED) visit, hospitalization of any duration for acute illness management, or death through day 29 and progression to severe or critical respiratory COVID-19 requiring supplemental oxygen or mechanical ventilation.

RESULTS: Enrollment was stopped early for efficacy at the prespecified interim analysis. Among 1057 patients randomized (median age, 53 years [IQR, 42-62], 20% were ≥65 years of age, and 65% Latinx), the median duration of follow-up was 103 days for sotrovimab and 102 days for placebo. All-cause hospitalization lasting longer than 24 hours or death was significantly reduced with sotrovimab (6/528 [1%]) vs placebo (30/529 [6%]) (adjusted relative risk [RR], 0.21 [95% CI, 0.09 to 0.50]; absolute difference, -4.53% [95% CI, -6.70% to -2.37%]; P < .001). Four of the 5 secondary outcomes were statistically significant in favor of sotrovimab, including reduced ED visit, hospitalization, or death (13/528 [2%] for sotrovimab vs 39/529 [7%] for placebo; adjusted RR, 0.34 [95% CI, 0.19 to 0.63]; absolute difference, -4.91% [95% CI, -7.50% to -2.32%]; P < .001) and progression to severe or critical respiratory COVID-19 (7/528 [1%] for sotrovimab vs 28/529 [5%] for placebo; adjusted RR, 0.26 [95% CI, 0.12 to 0.59]; absolute difference, -3.97% [95% CI, -6.11% to -1.82%]; P = .002). Adverse events were infrequent and similar between treatment groups (22% for sotrovimab vs 23% for placebo); the most common events were diarrhea with sotrovimab (n = 8; 2%) and COVID-19 pneumonia with placebo (n = 22; 4%).

CONCLUSIONS AND RELEVANCE: Among nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression, a single intravenous dose of sotrovimab, compared with placebo, significantly reduced the risk of a composite end point of all-cause hospitalization or death through day 29. The findings support sotrovimab as a treatment option for nonhospitalized, high-risk patients with mild to moderate COVID-19, although efficacy against SARS-CoV-2 variants that have emerged since the study was completed is unknown.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04545060.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022. PMID: 35285853. doi:10.1001/jama.2022.2832

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。